MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 25.02.2026
Celldex Therapeutics Anteile 2011-2026 | CLDX
Anteile Jährlich Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.4 M | 64.4 M | 48.4 M | 46.9 K | 42.9 K | 29.6 K | 14.5 M | 10.4 M | 8.57 M | 6.77 M | 6.47 M | 5.96 M | 5.32 M | 3.85 M | 2.63 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 66.4 M | 29.6 K | 16.3 M |
Anteile Vierteljährlich Celldex Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.4 K | 66.4 K | 66.4 K | 66.4 M | 66.3 K | 66 K | 58.9 K | 55.9 M | 47.3 K | 47.3 K | 47.2 K | 47.2 M | 46.9 K | 46.8 K | 46.7 K | 46.7 M | 45.5 M | 39.6 M | 39.6 M | 39.6 M | 39.3 M | 22.1 M | 17.4 M | 17 M | 15.3 M | 14 M | 12.3 M | 12 M | 10.9 M | 9.83 M | 9.37 M | 9.23 M | 130 M | 125 M | 123 M | 121 M | 101 M | 98.8 M | 98.7 M | 98.7 M | 98.6 M | 98.5 M | 92.4 M | 89.6 M | 89.4 M | 89.4 M | 89.3 M | 89.2 M | 81 M | 80.9 M | 74 M | 64.4 M | 59.5 M | 58.7 M | 50.1 M | 44.2 M | 44.1 M | 37.5 M | 32 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 130 M | 46.7 K | 47.9 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
7.35 M | $ 0.89 | 1.48 % | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
Evogene Ltd.
EVGN
|
40.4 M | $ 0.75 | -4.66 % | $ 27.9 M |  Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
166 M | $ 22.2 | -2.07 % | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
65.5 M | $ 27.86 | -1.97 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Innate Pharma S.A.
IPHA
|
79.5 M | $ 1.49 | 6.43 % | $ 235 M | France |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
244 M | $ 101.57 | -0.48 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
9.27 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 2.98 | 2.41 % | $ 4.91 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
107 M | $ 4.05 | -0.98 % | $ 433 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 22.37 | -3.95 % | $ 2.85 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
34.7 B | $ 32.99 | -0.39 % | $ 286 B | France |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Avenue Therapeutics
ATXI
|
3.13 M | - | -52.27 % | $ 4.45 M | USA |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.41 | -4.73 % | $ 375 M | Britain |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Pharming Group N.V.
PHAR
|
642 M | $ 16.36 | -0.4 % | $ 7.59 B |  Niderland |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |